NLTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NLTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Neoleukin Therapeutics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Neoleukin Therapeutics's Total Assets for the quarter that ended in Sep. 2023 was $91.80 Mil. Therefore, Neoleukin Therapeutics's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.
Asset Turnover is linked to ROE % through Du Pont Formula. Neoleukin Therapeutics's annualized ROE % for the quarter that ended in Sep. 2023 was -23.39%. It is also linked to ROA % through Du Pont Formula. Neoleukin Therapeutics's annualized ROA % for the quarter that ended in Sep. 2023 was -19.72%.
The historical data trend for Neoleukin Therapeutics's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neoleukin Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Asset Turnover | Get a 7-Day Free Trial | 0.27 | - | - | - | - |
Neoleukin Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Asset Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Neoleukin Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Neoleukin Therapeutics's Asset Turnover falls into.
Asset Turnover measures how quickly a company turns over its asset through sales.
Neoleukin Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Dec. 2022 ) | / | ( (Total Assets (A: Dec. 2021 ) | + | Total Assets (A: Dec. 2022 )) | / count ) |
= | 0 | / | ( (163.263 | + | 115.948) | / 2 ) |
= | 0 | / | 139.6055 | |||
= | 0.00 |
Neoleukin Therapeutics's Asset Turnover for the quarter that ended in Sep. 2023 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Sep. 2023 ) | / | ( (Total Assets (Q: Jun. 2023 ) | + | Total Assets (Q: Sep. 2023 )) | / count ) |
= | 0 | / | ( (94.005 | + | 89.586) | / 2 ) |
= | 0 | / | 91.7955 | |||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Neoleukin Therapeutics (NAS:NLTX) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
Neoleukin Therapeutics's annulized ROE % for the quarter that ended in Sep. 2023 is
ROE %** | (Q: Sep. 2023 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | -18.104 | / | 77.4055 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (-18.104 / 0) | * | (0 / 91.7955) | * | (91.7955/ 77.4055) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | % | * | 0 | * | 1.1859 |
= | ROA % | * | Equity Multiplier | ||
= | -19.72 % | * | 1.1859 | ||
= | -23.39 % |
Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Neoleukin Therapeutics's annulized ROA % for the quarter that ended in Sep. 2023 is
ROA % | (Q: Sep. 2023 ) | ||
= | Net Income | / | Total Assets |
= | -18.104 | / | 91.7955 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (-18.104 / 0) | * | (0 / 91.7955) |
= | Net Margin % | * | Asset Turnover |
= | % | * | 0 |
= | -19.72 % |
Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of Neoleukin Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Baker Bros. Advisors Lp | 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Sean Michael Smith | officer: Principal Accounting Officer | C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102 |
Priti Patel | officer: Chief Medical Officer | C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102 |
Erin Lavelle | director | C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Donna Cochener | officer: General Counsel, SVP Legal | C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102 |
Rohan Palekar | director | 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105 |
Jonathan G Drachman | director, officer: See Remarks | 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Carl Walkey | officer: Senior Vice President | C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Robert Ho | officer: Chief Financial Officer | 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Holly Vance | officer: General Counsel | C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102 |
Martin Babler | director | C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Erin M. Lavelle | director | 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Redmile Group, Llc | 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Jeremy Green | 10 percent owner | 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001 |
Sarah B. Noonberg | director | 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By PurpleRose PurpleRose • 08-03-2022
By PRNewswire • 08-15-2023
By Business Wire • 07-25-2023
By Marketwired • 08-17-2023
By PurpleRose PurpleRose • 08-09-2022
By Value_Insider Value_Insider • 12-12-2022
By GuruFocusNews GuruFocusNews • 06-08-2022
By Business Wire • 07-18-2023
By Marketwired • 07-18-2023
By GuruFocusNews GuruFocusNews • 05-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.